Latest News for: refractory
Edit
Intimation of closure of trading window of Dalmia Bharat Refractories Limited (Dalmia Bharat Refractories Ltd)
Public Technologies 24 Dec 2025
Edit
Newspaper publication intimation regarding the ensuing Extra Ordinary General Meeting ('EGM') (Dalmia Bharat Refractories Ltd)
Public Technologies 24 Dec 2025
) ... 7, Lyons Range, ... Intimation of publication of notice of the 01stExtra Ordinary General Meeting of Dalmia Bharat Refractories Limited ('Company') for FY 2025-2026 ... Thanking you, For Dalmia Bharat Refractories Limited ... th ... Dalmia Bharat Refractories Ltd.
Edit
The Milton Standard Journal
23 Dec 2025
Agenus Reports Deep, Durable Responses with Botensilimab + Balstilimab in Highly Refractory Ovarian Cancer, Published ...
Edit
The Eagle-Tribune
22 Dec 2025
FDA Approves Genentech’s Lunsumio VELO™ for Subcutaneous Use in Relapsed or Refractory Follicular Lymphoma
Edit
FDA approves Roche’s Lunsumio VELO™ for subcutaneous use in relapsed or refractory follicular lymphoma
Nasdaq Globe Newswire 22 Dec 2025
RHHBY) announced today that the US Food and Drug Administration (FDA) has approved CD20xCD3 bispecific Lunsumio VELO™ ...
Edit
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma
Pharmiweb 22 Dec 2025
today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL).
Edit
Incyte Announces European Commission Approval of Minjuvi� (tafasitamab) for the Treatment of Relapsed or Refractory ...
Business Wire 18 Dec 2025
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces European Commission Approval of Minjuvi� (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma ... .
Edit
Qihan Biotech Initiates Dosing in Phase I/IIa Clinical Trial with Off-the-Shelf Allogeneic CAR-T Therapy for Refractory Systemic Lupus Erythematosus
Pharmiweb 18 Dec 2025
We look forward to evaluating the clinical potential of this off-the-shelf CAR-T cell product, which could provide a novel and more accessible treatment option for patients with refractory systemic lupus erythematosus.”.
Edit
Refractories Market Size to Reach USD 56.99 Billion by 2033 Due to High Demand for ...
Nasdaq Globe Newswire 17 Dec 2025
Refractories market growth is driven by rising steel, cement, and energy demand, supported by industrial expansion and high-temperature process needs ... .
Edit
Cadillac News
17 Dec 2025
Incyte Announces European Commission Approval of Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory ...
Edit
EpilepsyGTx Raises $33 Million Series A to Develop Single Dose Gene Therapy for Focal Refractory Epilepsy
Business Wire 10 Dec 2025
Edit
Diakonos Oncology Awarded Multi-Million-Dollar Research Grant by the Cancer Prevention and Research Institute of Texas to Advance DOC1021 in Refractory Melanoma
PR Newswire 10 Dec 2025
CPRIT award exceeds $7 million, with Diakonos selected as one of only nine awardees from a pool of 164 applicants Funding will support advancing DOC1021 into a Phase 1/2 clinical trial for patients with refractory melanoma.
Edit
Refractory Epilepsy Treatment: Transforming Healthcare with Personalized Therapy
Nasdaq Globe Newswire 09 Dec 2025
Edit
Citizen Tribune
09 Dec 2025
Tec-Dara Combination Offers Substantial Improvement Over Standard Second-Line Therapies for Relapsed or Refractory Multiple Myeloma
... with relapsed/refractory Multiple Myeloma (RRMM).
- 1
- 2
- Next page »